Table 1. Comparison of the clinical and pathologic characteristics and disease outcome of all included carcinomas with respect to the L1CAM expression.
| All | L1CAM− | L1CAM+ | Pa | |
|---|---|---|---|---|
| Number of patients | 1199 | 999 (83%) | 200 (17%) | |
| Median age (years) | 64 (range 31–93) | 63 (range 31–93) | 69 (range 39–93) | <0.01 |
| Median follow-upb (months) | 62 (range 0–229) | 64 (1–229) | 50 (range 0–185) | <0.01 |
| Treatment | ||||
| Lymphadenectomy | 795 (66%) | 645 (65%) | 150 (75%) | <0.01 |
| Radiotherapy | 563 (47%) | 467 (47%) | 96 (48%) | 0.86 |
| Chemotherapy | 123 (10%) | 72 (7%) | 51 (26%) | <0.01 |
| FIGO stage | ||||
| I | 965 (80%) | 849 (85%) | 116 (58%) | <0.01 |
| II | 74 (6%) | 58 (6%) | 16 (8%) | |
| III | 125 (10%) | 76 (8%) | 49 (25%) | |
| IV | 35 (3%) | 16 (2%) | 19 (10%) | |
| Histology | ||||
| Endometrioid | 1095 (91%) | 973 (97%) | 122 (61%) | <0.01 |
| Non-endometrioid | 104 (9%) | 26 (3%) | 78 (39%) | |
| Grade | ||||
| 1 | 467 (39%) | 441 (44%) | 26 (13%) | <0.01 |
| 2 | 474 (40%) | 417 (42%) | 57 (29%) | |
| 3 | 258 (22%) | 141 (14%) | 117 (59%) | |
| Myometrial invasion | ||||
| <1/2 | 746 (62%) | 656 (66%) | 90 (45%) | <0.01 |
| ⩾1/2 | 453 (38%) | 343 (34%) | 110 (55%) | |
| LVSI | ||||
| No | 813 (68%) | 723 (88%) | 90 (60%) | <0.01 |
| Yes | 162 (14%) | 101 (12%) | 61 (41%) | |
| Unknown | 224 | 175 | 49 | |
| Outcome | ||||
| Residual disease | 40 (3%) | 15 (2%) | 25 (12.5%) | <0.01 |
| Recurrence | 158 (13%) | 100 (10%) | 58 (33%) | <0.01 |
| Locoregional | 76 (7%) | 57 (6%) | 19 (11%) | 0.02 |
| Distant | 98 (8%) | 53 (5%) | 45 (26%) | <0.01 |
| Deceased | 171 (14%) | 104 (10%) | 67 (34%) | <0.01 |
| Endometrial cancer | 99 (8%) | 48 (5%) | 51 (26%) | <0.01 |
Abbreviations: FIGO=International Federation of Gynaecology and Obstetrics; L1CAM=L1 cell adhesion molecule; LVSI=lymphovascular space invasion.
a
P-value for the Mann–Whitney U-test for continuous variables, and χ2 test for categorical variables. Bold values indicate that the differences were considered to be significant.
b
Median follow-up including deceased patients.